Journal article
A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29.
Abstract
7511
Authors
Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F
Journal
Journal of Clinical Oncology, Vol. 30, No. 15_suppl, pp. 7511–7511
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2012
DOI
10.1200/jco.2012.30.15_suppl.7511
ISSN
0732-183X